Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iressa in Advanced Salivary Gland Cancer
NCT00509002Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2004
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gefitinib in salivary gland cancer (SGC), sponsored by University of Texas MD Anderson Cancer Center. Started May 2004; status: completed.
02
Drugs
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT00509002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00509002.